Venous-Only Approach for Transcatheter Patent Ductus Arteriosus Closure in Infants: Is It Time for Change?

仅采用静脉途径经导管封堵婴儿动脉导管未闭:是时候做出改变了吗?

阅读:2

Abstract

BACKGROUND: The standard approach for transcatheter closure of patent ductus arteriosus (TC-PDA) requires arterial access and is associated with the risk of arterial injury, a metric tracked by national quality improvement registries. Venous-only TC-PDA in premature infants is performed successfully without arterial access. It was hypothesized that PDA closure in infants could be performed safely and effectively without arterial access. METHODS: This is a single-center, retrospective, institutional review board-approved study. All infants weighing 2 to 10 kg who underwent TC-PDA closure between January 2019 and December 2024 were included in the study. Patients who underwent concurrent procedures and those with complex heart disease were excluded from the study. TC-PDA was performed using the standard approach or venous-only approach at the discretion of the attending cardiologist. RESULTS: In total, 150 patients underwent TC-PDA: 59 patients (19 male) underwent closure using the standard approach and 91 patients (35 male) using the venous-only approach. There was no difference in the minimum patent ductus arteriosus diameter. There was no pulse loss in the venous-only cohort; 1 patient (1.7%) treated with the standard approach had clinical symptomatic arterial injury requiring therapy. The venous-only cohort was younger, weighed less, and had lower radiation exposure, contrast use, shorter total procedure, and total sheath time. There was no difference in other adverse procedural outcomes. CONCLUSIONS: Venous-only approach for TC-PDA closure in infants is as effective and efficient as the standard approach. The added advantage of eliminating arterial injury increases the safety for TC-PDA in small infants.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。